
Convicted “Pharma Bro” Martin Shkreli and his attorneys are asking a judge to compel seven state attorneys general who sued him and the company he founded, Vyera Pharmaceuticals, to produce documents deemed crucial in an ongoing federal antitrust lawsuit over drug price hikes, reported Bloomberg.
The states, which include California and Virginia, have “refused” to provide any discovery related to purchases and reimbursements of Daraprim, the parasitic infection treatment drug at the center of the case, Vyera’s attorney, Steven Reed of Morgan, Lewis & Bockius LLP, said Monday, June 28, in a letter filed with the US District Court for the Southern District of New York.
The states, led by New York’s Attorney General Letitia James, have disputed such claims. Shkreli and Vyera “wrongly contend” that the states haven’t produced all of the files in their possession, the states wrote in their own letter to US District Court Judge Denise Cote, who is presiding over the case.
“The information that Defendants are seeking from state agencies is not relevant, and the data and information relevant to the calculation of Defendants’ ill-gotten gains are in Defendants’ possession, custody and control- not ours,” Elinor Hoffmann, the acting chief of New York’s antitrust bureau, wrote Monday in a letter.
In January, the Federal Trade Commission and New York sued Vyera—formerly known as Turing Pharmaceuticals—along with co-owners Shkreli and Kevin Mulleady, for allegedly violating antitrust law when acquiring and then immediately raising the price of Daraprim by nearly 4,000%.
Full Content: Baker McKenzie
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Fortnite Returns to Apple’s U.S. App Store After Five-Year Ban
May 21, 2025 by
CPI
Federal Court to Hear Case on Trump’s Firing of FTC Democrats
May 20, 2025 by
CPI
UK Government Suffers Third Successive Defeat on Data (Use and Access) Bill
May 20, 2025 by
CPI
Sex Toy Retailer Says Google Breaches EU Digital Market Rules
May 20, 2025 by
CPI
Latham & Watkins Expands Brussels Antitrust Team
May 20, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Healthcare Antitrust
May 14, 2025 by
CPI
Healthcare & Antitrust: What to Expect in the New Trump Administration
May 14, 2025 by
Nana Wilberforce, John W O'Toole & Sarah Pugh
Patent Gaming and Disparagement: Commission Fines Teva For Improperly Protecting Its Blockbuster Medicine
May 14, 2025 by
Blaž Višnar, Boris Andrejaš, Apostolos Baltzopoulos, Rieke Kaup, Laura Nistor & Gianluca Vassallo
Strategic Alliances in the Pharma Sector: An EU Competition Law Perspective
May 14, 2025 by
Christian Ritz & Benedikt Weiss
Monopsony Power in the Hospital Labor Market
May 14, 2025 by
Kevin E. Pflum & Christian Salas